PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program Pharmaceutical Investing
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY Life Science Investing
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM Life Science Investing
Seaweed Consultancy Renewed – Focus on Blockchain, Carbon Credits and AI to Drive R&D Program SmartNews
Zero Candida Announces Full Transaction and Being Trading November 25th on the TSX Venture Exchange (Canada) Medical Device Investing
